Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & Administrative
Others
Ratios

Pasithea Therapeutics (KTTA) Net Income towards Common Stockholders (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Net Income towards Common Stockholders for 4 consecutive years, with -$3.2 million as the latest value for Q4 2024.

  • Quarterly Net Income towards Common Stockholders fell 18708.29% to -$3.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$13.9 million through Dec 2024, down 2963.29% year-over-year, with the annual reading at -$20.4 million for FY2025, 46.91% down from the prior year.
  • Net Income towards Common Stockholders hit -$3.2 million in Q4 2024 for Pasithea Therapeutics, down from -$3.0 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $630143.0 in Q4 2021 to a low of -$3.9 million in Q2 2024.
  • Historically, Net Income towards Common Stockholders has averaged -$1.3 million across 4 years, with a median of -$549609.0 in 2021.
  • Biggest five-year swings in Net Income towards Common Stockholders: surged 98.41% in 2023 and later crashed 18708.29% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at $630143.0 in 2021, then crashed by 268.9% to -$1.1 million in 2022, then soared by 98.41% to -$16895.0 in 2023, then plummeted by 18708.29% to -$3.2 million in 2024.
  • Business Quant data shows Net Income towards Common Stockholders for KTTA at -$3.2 million in Q4 2024, -$3.0 million in Q3 2024, and -$3.9 million in Q2 2024.